(Q37501707)

20 August 2017

0 references

1 reference

title

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis (English)

1 reference

20 August 2017

0 references

0 references

1 reference

Sanjaykumar Hapani

1

1 reference

20 August 2017

David Chu

series ordinal

2

1 reference

20 August 2017

Shenhong Wu

series ordinal

3

1 reference

20 August 2017

language of work or name

1 reference

1 June 2009

1 reference

Lancet Oncology Commission

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

559-568

1 reference

Tumor angiogenesis: therapeutic implications

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Selecting and appraising studies for a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Quantitative synthesis in systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Managing patients treated with bevacizumab combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

[Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bowel perforation in non-small cell lung cancer after bevacizumab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Peptic ulcer perforation associated with steroid use.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Emergency laparotomy for spontaneous intestinal and colonic perforations in cancer patients receiving corticosteroids and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Gastrointestinal perforation due to bevacizumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Gastrointestinal perforations associated with interleukin-2 administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970112-3

7 January 2021

10.1016/S1470-2045(09)70112-3

Identifiers

DOI

1 reference

20 August 2017

1 reference